Anti -MYF6 (Myogenic Factor 6, Myf-6, Class C Basic Helix-loop-helix Protein 4, bHLHc4, Muscle-specific Regulatory Factor 4, BHLHC4, MRF4)

For Research Use Only. Not for use in diagnostic procedures.

Chromosome: 12; NC_000012.11 (81101408..81103257). Location: 12q21

Monoclonal

IgG2a, k

1H3

Mouse

Recognizes human MYF6.

Purified
Purified.

Supplied as a liquid in PBS, pH 7.2.

May be stored at 4 degree C for short-term only. Aliquot to avoid repeated freezing and thawing. Store at -20 degree C. Aliquots are stable for at least 12 months. For maximum recovery of product, centrifuge the original vial after thawing and prior to removing the cap.

Small volumes of anti-MYF6 antibody vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.

MYF6 is a part of the myogenic basic helix loop helix family of transcription factors, and can activate the muscle differentiation program. It is thought to induce fibroblasts to differentiate into myoblasts. Defects in MYF6 are the cause of centronuclear myopathy.

Antibodies; Abs to Transcription Factors

ELISA (EL/EIA), Western Blot (WB)

Suitable for use in ELISA and Western Blot.

26,953 Da[Similar Products]

myogenic factor 6 (herculin)

myogenic factor 6; myf-6; muscle-specific regulatory factor 4; class C basic helix-loop-helix protein 4

Myogenic factor 6

BHLHC4; MRF4??[Similar Products]

MYF6_HUMAN

The protein encoded by this gene is a probable basic helix-loop-helix (bHLH) DNA binding protein involved in muscle differentiation. The encoded protein likely acts as a heterodimer with another bHLH protein. Defects in this gene are a cause of autosomal dominant centronuclear myopathy (ADCNM). [provided by RefSeq]

Myf-6: Involved in muscle differentiation (myogenic factor). Induces fibroblasts to differentiate into myoblasts. Probable sequence specific DNA-binding protein. Defects in MYF6 may be a cause of centronuclear myopathy type 3 (CNM3). A congenital muscle disorder characterized by progressive muscular weakness and wasting involving mainly limb girdle, trunk, and neck muscles. It may also affect distal muscles. Weakness may be present during childhood or adolescence or may not become evident until the third decade of life. Ptosis is a frequent clinical feature. The most prominent histopathologic features include high frequency of centrally located nuclei in muscle fibers not secondary to regeneration, radial arrangement of sarcoplasmic strands around the central nuclei, and predominance and hypotrophy of type 1 fibers.

Protein type: DNA-binding; Transcription factor

Chromosomal Location of Human Ortholog: 12q21

Cellular Component: nucleoplasm; nucleus

Molecular Function: RNA polymerase II transcription factor activity, enhancer binding; protein heterodimerization activity; transcription factor activity

Biological Process: transcription from RNA polymerase II promoter; regulation of transcription from RNA polymerase II promoter; skeletal muscle development; somitogenesis; muscle cell differentiation; positive regulation of skeletal muscle fiber development; muscle cell fate commitment; positive regulation of muscle cell differentiation; skeletal muscle regeneration; positive regulation of transcription from RNA polymerase II promoter; negative regulation of transcription, DNA-dependent; positive regulation of myoblast differentiation

Disease: Myopathy, Centronuclear, 3

All of MyBioSource's Products are for scientific laboratory research purposes and are not for diagnostic, therapeutics, prophylactic or in vivo use. Through your purchase, you expressly represent and warrant to MyBioSource that you will properly test and use any Products purchased from MyBioSource in accordance with industry standards. MyBioSource and its authorized distributors reserve the right to refuse to process any order where we reasonably believe that the intended use will fall outside of our acceptable guidelines.

While every efforts were made to ensure the accuracy of the information provided in this datasheet, MyBioSource will not be liable for any omissions or errors contained herein. MyBioSource reserves the right to make changes to this datasheet at any time without prior notice.

It is the responsibility of the customer to report product performance issues to MyBioSource within 30 days of receipt of the product. Please visit our Terms & Conditions page for more information.